<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949516</url>
  </required_header>
  <id_info>
    <org_study_id>WKUH 2021-06-004</org_study_id>
    <nct_id>NCT04949516</nct_id>
  </id_info>
  <brief_title>Mono Antiplatelet and Colchicine Therapy</brief_title>
  <acronym>MACT</acronym>
  <official_title>Aspirin-free Therapy After Successful Percutaneous Coronary Intervention for Acute Coronary Syndrome: the MACT (Mono Antiplatelet and Colchicine Therapy) Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wonkwang University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wonkwang University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of aspirin-free, P2Y12&#xD;
      inhibitor single antiplatelet and colchicine treatment in patients with acute coronary&#xD;
      syndrome treated with drug-eluting stents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After successful drug-eluting stent implantation for acute coronary syndrome, screening for&#xD;
      study subject enrollment is performed. For those who submitted written informed consent,&#xD;
      aspirin is stopped the day after the intervention, and colchicine 0.6mg once daily is&#xD;
      started. The P2Y12 inhibitor, prasugrel or ticagrelor, for single antiplatelet therapy&#xD;
      remains. For the duration of hospital stay, platelet reactivity using VerifyNow test and&#xD;
      C-reactive protein are measured. Aspirin may be restarted at the discretion of the&#xD;
      investigator based on results of the platelet function test. C-reactive protein is remeasured&#xD;
      30 days after the intervention. Clinical follow-up is performed 30 days and 90 days after the&#xD;
      intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">June 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcomes - Definite, probable, and possible stent thrombosis (Academic Research Consortium)</measure>
    <time_frame>Assessed at hospital stay and 30/90 days after stent implantation</time_frame>
    <description>Definite, probable, and possible stent thrombosis (Academic Research Consortium)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes - Target vessel failure</measure>
    <time_frame>Assessed at hospital stay and 30/90 days after stent implantation</time_frame>
    <description>Composite time-to-first event rate of cardiac death, target vessel-myocardial infarction (TV-MI), or ischemia driven-target vessel revascularization (ID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes - Target lesion failure</measure>
    <time_frame>Assessed at hospital stay and 30/90 days after stent implantation</time_frame>
    <description>Composite time-to-first event rate of cardiac death, TV-MI, or ischemia driven-target lesion revascularization (ID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes - All-cause mortality</measure>
    <time_frame>Assessed at hospital stay and 30/90 days after stent implantation</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes - Cardiac and non-cardiac mortality</measure>
    <time_frame>Assessed at hospital stay and 30/90 days after stent implantation</time_frame>
    <description>Cardiac and non-cardiac mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes - All myocardial infarction</measure>
    <time_frame>Assessed at hospital stay and 30/90 days after stent implantation</time_frame>
    <description>All myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes - TV-MI and non-TV-MI</measure>
    <time_frame>Assessed at hospital stay and 30/90 days after stent implantation</time_frame>
    <description>TV-MI and non-TV-MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes - All revascularization</measure>
    <time_frame>Assessed at hospital stay and 30/90 days after stent implantation</time_frame>
    <description>All revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes - ID-TVR, ID-TLR and ID-non-TLR TVR</measure>
    <time_frame>Assessed at hospital stay and 30/90 days after stent implantation</time_frame>
    <description>ID-TVR, ID-TLR and ID-non-TLR TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes - Type 1, type 2, type 3, type 4, and type 5 bleeding (Bleeding Academic Research Consortium)</measure>
    <time_frame>Assessed at hospital stay and 30/90 days after stent implantation</time_frame>
    <description>Type 1, type 2, type 3, type 4, and type 5 bleeding (Bleeding Academic Research Consortium)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory outcomes - P2Y12 reaction unit</measure>
    <time_frame>Assessed at hospital stay</time_frame>
    <description>P2Y12 reaction unit using VerifyNow P2Y12 rapid analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory outcomes - Percent platelet inhibition</measure>
    <time_frame>Assessed at hospital stay</time_frame>
    <description>Percent platelet inhibition using VerifyNow P2Y12 rapid analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory outcomes - C-reactive protein</measure>
    <time_frame>Assessed at hospital stay and 30 days after stent implantation</time_frame>
    <description>C-reactive protein</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Drug-Eluting Stents</condition>
  <arm_group>
    <arm_group_label>Mono Antiplatelet and Colchicine Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin-free, single P2Y12 inhibitor (prasugrel or ticagrelor) and colchicine treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin is discontinued the day after drug-eluting stent implantation</description>
    <arm_group_label>Mono Antiplatelet and Colchicine Therapy</arm_group_label>
    <other_name>Aspirin stop</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine is started the day after drug-eluting stent implantation</description>
    <arm_group_label>Mono Antiplatelet and Colchicine Therapy</arm_group_label>
    <other_name>Colchicine start</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Successful PCI with drug-eluting stent for NSTE-ACS or STEMI&#xD;
&#xD;
          -  Provision of written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac arrest or cardiogenic shock&#xD;
&#xD;
          -  Age &lt;19 or &gt;90 years old&#xD;
&#xD;
          -  Severe liver impairment&#xD;
&#xD;
          -  Severe renal impairment (eGFR &lt;30 mL/min/1.73 m2)&#xD;
&#xD;
          -  Intolerance of prasugrel, ticagrelor, or colchicine&#xD;
&#xD;
          -  History of intracranial hemorrhage&#xD;
&#xD;
          -  Active bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Yul Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonkwang University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung-Yul Lee, MD</last_name>
    <phone>82-10-4211-6516</phone>
    <email>seungyul79@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wonkwang University Hospital</name>
      <address>
        <city>Iksan</city>
        <zip>54538</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Yul Lee, MD</last_name>
      <phone>82-10-4211-6516</phone>
      <email>seungyul79@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wonkwang University Hospital</investigator_affiliation>
    <investigator_full_name>Seung-Yul Lee</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Platelet Aggregation Inhibitors</keyword>
  <keyword>Colchicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

